Before the vaccine administration, the percentages of ICOS+PD-1+ Tregs within the CD4+ population were significantly decreased in IPF patients (0.33% vs 0.64%; p=0.02) when compared to control. This evidence concerns the gene ICOS and idiopathic pulmonary fibrosis.